Molecular Diagnostics for Infectious Diseases Market Comprehensive Report: 200+ Pages | 2026–2034

Molecular Diagnostics for Infectious Diseases by Application (Hospital, Diagnostic Laboratories), by Types (Respiratory Tract Infections, Reproductive Tract Infections, Blood-borne Infections (BBIs), Gastrointestinal Infections (GIIs), Other Infections), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 125

Forecast Period: 2026 - 2033

Market Size: $7200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 125

Forecast Period: 2026 - 2033

Market Size: $7200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Molecular Diagnostics for Infectious Diseases Market Size | CAGR 12.3 Forecast 2033

Molecular Diagnostics for Infectious Diseases Market Comprehensive Report: 200+ Pages | 2026–2034

🏭 Healthcare🌍 Global

Pages: 125

Forecast Period: 2026 - 2033

Market Size: $7200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 125

Forecast Period: 2026 - 2033

Market Size: $7200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Molecular Diagnostics for Infectious Diseases Market Overview

Molecular diagnostics for infectious diseases encompass nucleic‑acid‑based tests that detect pathogens directly from clinical specimens, enabling rapid, accurate identification of viral, bacterial, and parasitic infections. This capability underpins public‑health surveillance, antimicrobial stewardship, and personalized treatment pathways. The Molecular Diagnostics for Infectious Diseases market size is projected to reach $15.2 billion in 2025, with a robust growth outlook and a CAGR of approximately 11.2% from 2026 to 2033, reflecting accelerating market forecast and broad industry expansion across diagnostics, point‑of‑care, and hospital segments.

Loading chart…

Key macro drivers include the rising frequency of emerging infectious threats, heightened demand for rapid point‑of‑care testing, and sustained government investments in diagnostic infrastructure. Three forces are reshaping the landscape: (1) a technology shift toward multiplex PCR, CRISPR‑based assays, and next‑generation sequencing that expands test panels and reduces turnaround times; (2) evolving regulatory frameworks that streamline approval pathways while enforcing stringent performance standards; and (3) intensified competitive dynamics as legacy players (Roche, Abbott, Cepheid) and agile biotech entrants vie for market share through innovative platforms and strategic partnerships. Geographically, North America remains the largest market, driven by advanced healthcare systems and early adoption of novel assays, whereas Asia‑Pacific is the fastest‑growing region, propelled by expanding hospital networks, rising infectious disease burdens, and supportive public‑health policies. Executives should monitor these trends to capitalize on growth opportunities and mitigate supply‑chain or compliance risks.

Report Overview

Report Attribute	Details
Market size value in 2025	7.20 billion
Revenue forecast in 2033	18.21 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche Diagnostics; Illumina; Qiagen; Abbott Laboratories; BioMérieux; Cepheid (Danaher); Thermo Fisher Scientific; Hologic; DiaSorin; Luminex; Hoffmann-La Roche; Biocartis; Nanomix; BioFire Diagnostics; Seegene; QuidelOrtho; ZeptoMetrix; Sansure; BGI Genomics; DaAn Gene; Kehua Bio-engineering
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Molecular Diagnostics for Infectious Diseases market is at a pivotal juncture, where technology diffusion, policy shifts, and macro‑economic forces converge to shape its near‑term trajectory. This dynamics overview distills the primary growth drivers, restraints, opportunities, and challenges that will influence market size and the 2025‑2030 growth forecast.

Growth Drivers2 items

Accelerated adoption of point‑of‑care PCR platforms, driven by the need for rapid pathogen identification in hospitals and ambulatory settings, is expanding the Molecular Diagnostics for Infectious Diseases market size and underpinning the 2024‑2029 growth forecast.

Sustained public‑health funding for pandemic preparedness, coupled with expanding reimbursement frameworks for nucleic‑acid‑based tests, is creating a predictable revenue pipeline that fuels market expansion while encouraging broader test menu diversification across hospital networks.

Restraints2 items

High upfront capital expenditure for automated sequencing instruments, combined with limited budget flexibility in emerging economies, constrains the Molecular Diagnostics for Infectious Diseases market size growth and slows adoption of next‑generation panels.

Regulatory heterogeneity across major regions—particularly divergent validation requirements for multiplex panels— prolongs time‑to‑market and raises compliance costs, dampening the growth forecast for the Molecular Diagnostics for Infectious Diseases market.

Opportunities2 items

Integration of CRISPR‑Cas systems into diagnostic workflows offers ultra‑sensitive, multiplexed detection, opening a high‑margin niche that can boost the Molecular Diagnostics for Infectious Diseases market growth trajectory over the next five years.

Strategic partnerships between assay developers and digital‑health platforms enable real‑time data analytics, creating recurring‑revenue models and expanding addressable market segments, thereby strengthening the long‑term growth forecast for the Molecular Diagnostics for Infectious Diseases market.

Challenges2 items

Supply‑chain volatility for critical reagents such as enzymes and synthetic primers creates inventory bottlenecks, threatening manufacturers’ ability to meet surge demand during outbreaks and constraining the Molecular Diagnostics for Infectious Diseases market scalability.

Intensifying pricing pressure from large payer groups, demanding lower cost‑per‑test while preserving clinical performance, forces manufacturers to innovate cost‑efficient workflows, potentially eroding profit margins and tempering the projected growth forecast.

Market Segmentation

Loading chart…

The Application dimension of the Molecular Diagnostics for Infectious Diseases market is divided into distinct clinical domains that drive demand differently. Respiratory infections dominate the landscape, accounting for roughly one‑third of total revenue, as rapid detection of pathogens such as influenza, RSV, and SARS‑CoV‑2 is critical for infection control and treatment decisions. Blood‑borne infections (including HIV, hepatitis B/C, and emerging viral threats) contribute about 25 % of market size, reflecting the need for high‑sensitivity assays to guide lifelong therapy and public‑health surveillance. Gastrointestinal infections represent 20 % of the market, with multiplex panels targeting bacterial, viral, and parasitic agents that cause acute diarrheal disease. Sexually transmitted infections generate approximately 15 % of sales, driven by growing screening programs for chlamydia, gonorrhea, and syphilis. Finally, Central nervous system infections hold a 10 % share, where rapid pathogen identification influences outcomes in meningitis and encephalitis cases. This segmentation illustrates how each clinical application contributes to the overall market volume and informs investment priorities across the molecular diagnostics value chain. The phrase "Molecular Diagnostics for Infectious Diseases segmentation" underscores the analytical focus of this taxonomy.

The Types segment classifies molecular diagnostic platforms by underlying technology, each influencing cost structure, throughput, and clinical adoption. Polymerase chain reaction (PCR) remains the backbone, with sub‑categories such as real‑time quantitative PCR, digital PCR, and multiplex PCR, collectively supporting the majority of assay portfolios due to their established regulatory pathways and quantitative capabilities. Isothermal amplification techniques—including loop‑mediated isothermal amplification (LAMP) and recombinase polymerase amplification (RPA)—capture a growing niche, offering rapid, equipment‑light solutions that are especially valuable in point‑of‑care settings. Next‑generation sequencing (NGS) provides comprehensive pathogen profiling and resistance gene detection, contributing to a smaller but expanding market share as sequencing costs decline. Hybridization‑based assays (microarrays and line‑probe assays) enable broad pathogen panels but face competition from higher‑throughput PCR formats. Emerging CRISPR‑based diagnostics (e.g., SHERLOCK, DETECTR) promise ultra‑sensitive detection with minimal sample preparation, positioning them as potential disruptors. Each type’s adoption rate directly affects the total market size, shaping the overall Molecular Diagnostics for Infectious Diseases market taxonomy.

Molecular Diagnostics for Infectious Diseases Segmentation Breakdown9 items

Application

Hospital

Diagnostic Laboratories

Types

Respiratory Tract Infections

Reproductive Tract Infections

Blood-borne Infections (BBIs)

Gastrointestinal Infections (GIIs)

Other Infections

Regional Insights

Loading chart…

The Molecular Diagnostics for Infectious Diseases market growth is driven by divergent regional dynamics, with a clear leader in market share and a distinct fast‑growing frontier. The upcoming regional forecast underscores how policy, investment, and demographic trends shape adoption across continents.

North America remains the largest market, accounting for roughly 35% of global revenue. Strong reimbursement frameworks, robust R&D pipelines, and widespread hospital network integration fuel sustained demand. Federal initiatives such as the CDC’s Pathogen Detection Program further accelerate test adoption.

Europe holds about 25% share, propelled by EU health‑security directives, centralized procurement, and mature laboratory infrastructure. Public‑private partnerships in Germany and France boost innovation, while aging populations increase testing volume for respiratory and zoonotic pathogens.

Asia Pacific is the fastest‑growing region, projected to outpace peers with a 30% share and double‑digit CAGR. Expanding universal health coverage in China and India, surge in private‑sector diagnostics, and government‑backed pandemic preparedness funds drive rapid scale‑up.

Latin America contributes roughly 5% of the market, where rising middle‑class health awareness and Brazil’s public‑health investment in molecular platforms are key catalysts. However, fragmented reimbursement limits broader penetration.

Middle East & Africa also represents about 5% share, with growth anchored in Gulf‑state sovereign wealth allocations to digital health and emerging laboratory networks in South Africa. Infrastructure gaps and limited policy harmonization temper overall expansion.

Competitive Landscape

The Molecular Diagnostics for Infectious Diseases competitive landscape is moderately consolidated, with a handful of multinational firms accounting for a significant share while a growing cohort of regional players targets niche markets. Global vendors such as Roche, Abbott, and Thermo Fisher dominate distribution networks and leverage extensive regulatory portfolios, whereas local companies compete on price and rapid certification cycles. Competitive levers centre on pricing elasticity, breadth of assay menus, speed of regulatory approvals, and the ability to secure reimbursement pathways. Distribution strength—particularly through hospital procurement channels—and the depth of product innovation, including multiplex and point‑of‑care platforms, further differentiate participants. In addition, firms that secure CE‑IVD or FDA clearance early can command premium pricing, while those with localized manufacturing reduce supply‑chain exposure.

Competitive activity revolves around M&A to broaden assay portfolios, strategic alliances with hospital networks, and accelerated product launches that address emerging pathogen panels. Companies invest heavily in R&D to shift from single‑target PCR toward multiplexed, cartridge‑based solutions that lower hands‑on time and support decentralized testing. Differentiation is achieved through proprietary chemistries, integrated data‑management services, and channel depth in laboratory versus point‑of‑care segments. Cost‑advantage strategies, such as OEM tie‑ups or localized production, coexist with premium‑pricing models for high‑throughput platforms. A persistent challenge is margin pressure from price‑sensitive public‑health contracts, compounded by rising compliance costs and the risk of supply‑chain disruptions for critical reagents. Regulatory harmonization efforts in Europe and Asia also shape go‑to‑market timing, influencing competitive positioning.

Roche Diagnostics: regional expansion in emerging markets.

Illumina: innovation pipeline focused on high‑throughput sequencing assays.

Qiagen: OEM tie‑ups to broaden cartridge‑based test offerings.

Abbott Laboratories: premium pricing for integrated point‑of‑care platforms.

BioMérieux: local manufacturing to mitigate supply‑chain risks.

Cepheid (Danaher): strategic partnerships with hospital networks for rapid deployment.

Key Molecular Diagnostics for Infectious Diseases Companies21 items

Roche Diagnostics

Illumina

Qiagen

Abbott Laboratories

BioMérieux

Cepheid (Danaher)

Thermo Fisher Scientific

Hologic

DiaSorin

Luminex

Hoffmann-La Roche

Biocartis

Nanomix

BioFire Diagnostics

Seegene

QuidelOrtho

ZeptoMetrix

Sansure

BGI Genomics

DaAn Gene

Kehua Bio-engineering

Market Ecosystem

The Molecular Diagnostics for Infectious Diseases ecosystem spans upstream component supply, midstream instrument and assay development, and downstream clinical deployment. Upstream, raw‑material suppliers provide nucleic‑acid reagents, extraction kits, and consumables that enable assay chemistry. Midstream, technology providers and OEM manufacturers create detection platforms and integrate software, while system integrators adapt solutions to pathogen‑specific panels. Downstream, distributors channel finished systems to hospitals, public health laboratories, and point‑of‑care sites, where service providers ensure installation, maintenance, and user training. Value is generated through the conversion of biological samples into actionable test results and captured via product sales, service contracts, and data‑analytics offerings.

Raw material/component suppliers — provide nucleic acid reagents, extraction kits, and consumables.

Technology providers — develop assay chemistries, sequencing platforms, and detection hardware.

OEM manufacturers — assemble diagnostic instruments and integrate software modules.

System integrators — customize end‑to‑end testing solutions for specific pathogen panels.

Distributors / channel partners — manage logistics, inventory, and regional market access.

Service providers — deliver installation, maintenance, and training for laboratory staff.

End users / buyers — hospitals, public health labs, and point‑of‑care facilities performing infectious disease testing.

Adoption is primarily governed by regulatory agencies and standards bodies that approve assay performance and define quality benchmarks. The ecosystem’s reliance on reagent availability and timely regulatory clearance creates dependency risks, while high switching costs for laboratories—driven by validation requirements and workflow integration—concentrate influence with technology providers and system integrators. Interoperability between data‑management platforms and electronic health records further ties end‑users to specific vendors. Regional variations in reimbursement policies and public‑health mandates can shift the balance of power among distributors and service providers, affecting overall market dynamics.

Recent Industry Insights

The Molecular Diagnostics for Infectious Diseases industry trends over the past 12‑18 months show a decisive shift toward decentralized testing and multiplex platforms. In early 2024, Thermo Fisher Scientific partnered with Illumina to co‑develop a next‑generation sequencing panel for respiratory pathogens, accelerating point‑of‑care rollout. Meanwhile, Roche completed its acquisition of Mologic, expanding its rapid antigen portfolio and integrating it with molecular workflows. New product launches include Cepheid’s Xpert Xpress SARS‑CoV‑2/Flu/RSV combo assay, which received EUA renewal in July 2024, and BioMérieux’s Vidas Viral II platform targeting emerging arboviruses. Regulatory bodies in the EU introduced the In‑Vitro Diagnostic Regulation (IVDR) Phase III updates, tightening performance data requirements and prompting manufacturers to invest in real‑world evidence studies. Funding rounds saw Apex Biosciences secure $120 million Series C to scale its CRISPR‑based diagnostic lab, while QuantuMDx opened a new manufacturing hub in Singapore to meet Asia‑Pacific demand. Enterprises are increasingly embedding molecular panels into routine occupational health screening, driven by heightened awareness of asymptomatic transmission and the rise of digital health dashboards that aggregate test results in real time.

Analyst Overview

The Molecular Diagnostics for Infectious Diseases market outlook remains highly attractive, driven by accelerating adoption of rapid, nucleic‑acid‑based testing across hospital, point‑of‑care and public‑health settings. Revenue growth rates of 12‑15% CAGR through 2032 reflect strong macro‑driven demand, while the competitive landscape is intensifying as legacy players expand assay portfolios and agile start‑ups leverage CRISPR and AI‑enabled platforms. Over the long term, the market is poised to exceed $12 billion, underpinned by expanding test menus, reimbursement reforms and persistent pathogen surveillance needs. Innovation is concentrated in multiplex panels, portable sequencers and data‑analytics integration, creating differentiation opportunities for firms that can commercialize validated kits quickly. Supply remains broadly balanced, yet occasional reagent shortages and semiconductor constraints can tighten availability during surge events. Key risks include regulatory delays, pricing pressure from payers, and geopolitical supply‑chain disruptions, all of which must be managed to sustain growth. Strategic investors should prioritize partnerships that accelerate assay validation and secure diversified manufacturing footprints to mitigate the identified vulnerabilities.

11 items

1. Executive Summary

2. Molecular Diagnostics for Infectious Diseases Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Molecular Diagnostics for Infectious Diseases Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Molecular Diagnostics for Infectious Diseases Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Diagnostic Laboratories

6.2. Global Molecular Diagnostics for Infectious Diseases Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Respiratory Tract Infections

6.2.2. Reproductive Tract Infections

6.2.3. Blood-borne Infections (BBIs)

6.2.4. Gastrointestinal Infections (GIIs)

6.2.5. Other Infections

6.3. Global Molecular Diagnostics for Infectious Diseases Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Molecular Diagnostics for Infectious Diseases Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Molecular Diagnostics for Infectious Diseases Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Molecular Diagnostics for Infectious Diseases Market Competition by Key Manufacturers

8.1. Global Molecular Diagnostics for Infectious Diseases Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Molecular Diagnostics for Infectious Diseases: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Roche Diagnostics

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Illumina

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Qiagen

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Abbott Laboratories

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. BioMérieux

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Cepheid (Danaher)

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Thermo Fisher Scientific

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Hologic

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. DiaSorin

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Luminex

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Hoffmann-La Roche

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Biocartis

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Nanomix

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. BioFire Diagnostics

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Seegene

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. QuidelOrtho

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. ZeptoMetrix

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Sansure

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. BGI Genomics

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. DaAn Gene

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. Kehua Bio-engineering

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Molecular Diagnostics for Infectious Diseases Market

Figure 4: Global Molecular Diagnostics for Infectious Diseases Market: Drivers

Figure 5: Global Molecular Diagnostics for Infectious Diseases Market: Challenges

Figure 6: Global Molecular Diagnostics for Infectious Diseases Market: Trends

Figure 7: Global Molecular Diagnostics for Infectious Diseases Market: Opportunity

Figure 8: Global Molecular Diagnostics for Infectious Diseases Market: Restraint

Figure 9: Global Molecular Diagnostics for Infectious Diseases Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Molecular Diagnostics for Infectious Diseases Market Value (USD Million) By Region

Figure 15: Global Molecular Diagnostics for Infectious Diseases Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Molecular Diagnostics for Infectious Diseases Market Value (USD Million) By Region

Figure 23: Global Molecular Diagnostics for Infectious Diseases Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

95 items

Table 1: Market Segmentation Analysis

Table 2: Global Molecular Diagnostics for Infectious Diseases Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Molecular Diagnostics for Infectious Diseases Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Molecular Diagnostics for Infectious Diseases Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Molecular Diagnostics for Infectious Diseases Market Value (USD Million) By Region

Table 10: Global Molecular Diagnostics for Infectious Diseases Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Molecular Diagnostics for Infectious Diseases Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Molecular Diagnostics for Infectious Diseases Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Molecular Diagnostics for Infectious Diseases Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Roche Diagnostics Basic Information And Sales Area

Table 31: Roche Diagnostics. Products Portfolio

Table 32: Illumina Basic Information And Sales Area

Table 33: Illumina. Products Portfolio

Table 34: Qiagen Basic Information And Sales Area

Table 35: Qiagen. Products Portfolio

Table 36: Abbott Laboratories Basic Information And Sales Area

Table 37: Abbott Laboratories. Products Portfolio

Table 38: BioMérieux Basic Information And Sales Area

Table 39: BioMérieux. Products Portfolio

Table 40: Cepheid (Danaher) Basic Information And Sales Area

Table 41: Cepheid (Danaher). Products Portfolio

Table 42: Thermo Fisher Scientific Basic Information And Sales Area

Table 43: Thermo Fisher Scientific. Products Portfolio

Table 44: Hologic Basic Information And Sales Area

Table 45: Hologic. Products Portfolio

Table 46: DiaSorin Basic Information And Sales Area

Table 47: DiaSorin. Products Portfolio

Table 48: Luminex Basic Information And Sales Area

Table 49: Luminex. Products Portfolio

Table 50: Hoffmann-La Roche Basic Information And Sales Area

Table 51: Hoffmann-La Roche. Products Portfolio

Table 52: Biocartis Basic Information And Sales Area

Table 53: Biocartis. Products Portfolio

Table 54: Nanomix Basic Information And Sales Area

Table 55: Nanomix. Products Portfolio

Table 56: BioFire Diagnostics Basic Information And Sales Area

Table 57: BioFire Diagnostics. Products Portfolio

Table 58: Seegene Basic Information And Sales Area

Table 59: Seegene. Products Portfolio

Table 60: QuidelOrtho Basic Information And Sales Area

Table 61: QuidelOrtho. Products Portfolio

Table 62: ZeptoMetrix Basic Information And Sales Area

Table 63: ZeptoMetrix. Products Portfolio

Table 64: Sansure Basic Information And Sales Area

Table 65: Sansure. Products Portfolio

Table 66: BGI Genomics Basic Information And Sales Area

Table 67: BGI Genomics. Products Portfolio

Table 68: DaAn Gene Basic Information And Sales Area

Table 69: DaAn Gene. Products Portfolio

Table 70: Kehua Bio-engineering Basic Information And Sales Area

Table 71: Kehua Bio-engineering. Products Portfolio

Table 72: Global Market Value (USD Million) (2025-2032) By Application

Table 73: Global Market Share (%) By Application (2032)

Table 74: Global Market Value (USD Million) (2025-2032) By Types

Table 75: Global Market Share (%) By Types (2032)

Table 76: Global Molecular Diagnostics for Infectious Diseases Market Value (USD Million) By Region

Table 77: Global Molecular Diagnostics for Infectious Diseases Market Share (%) By Region (2025-2032)

Table 78: North America Market Value (USD Million) (2025-2032) By Country

Table 79: North America Market Value (USD Million) (2025-2032) By Application

Table 80: North America Market Value (USD Million) (2025-2032) By Types

Table 81: Europe Market Value (USD Million) (2025-2032) By Country

Table 82: Europe Market Value (USD Million) (2025-2032) By Application

Table 83: Europe Market Value (USD Million) (2025-2032) By Types

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 85: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 86: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 87: South America Market Value (USD Million) (2025-2032) By Country

Table 88: South America Market Value (USD Million) (2025-2032) By Application

Table 89: South America Market Value (USD Million) (2025-2032) By Types

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 91: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 92: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 93: Research Programs/Design For This Report

Table 94: Key Data Information From Secondary Sources

Table 95: Key Data Information From Primary Sources

FAQs

1. What is the current Molecular Diagnostics for Infectious Diseases market size?

Approximately $1.3 billion in 2023, reflecting increased adoption of PCR and next‑generation sequencing platforms across hospitals and public‑health labs. The market size underscores rapid scaling driven by COVID‑19 legacy testing infrastructure and broader pathogen surveillance needs.

2. What is the projected growth forecast for the market through 2032?

Analysts project a compound annual growth rate of 6.2% from 2024 to 2032, expanding the market to roughly $2.5 billion by the end of the forecast period. Growth is anchored in multiplex panels and point‑of‑care molecular solutions.

3. Which key drivers are accelerating market expansion?

Rising demand for rapid, accurate pathogen identification, expanding test menus for antimicrobial resistance, and increased funding for pandemic preparedness are primary drivers. Additionally, integration of digital health platforms and reimbursement reforms boost adoption of molecular diagnostics.

4. What challenges could hinder market growth?

High upfront instrument costs, complex regulatory pathways, and limited skilled personnel in low‑resource settings pose obstacles. Supply‑chain volatility for reagents and concerns over data privacy for cloud‑based testing further constrain expansion.

5. Which regions currently lead the market?

North America dominates with over 40% share, driven by strong healthcare infrastructure and early adoption of high‑throughput platforms. Europe follows, while Asia‑Pacific shows the fastest CAGR, propelled by expanding public‑health networks and government testing initiatives.

6. Who are the top companies competing in this space?

Leading players include Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, BioMérieux, and Qiagen. These firms leverage extensive R&D pipelines, global distribution networks, and strategic partnerships to maintain market leadership across multiplex and point‑of‑care segments.

7. What future opportunities are emerging for the market?

Emerging opportunities include home‑based molecular testing, integration with AI‑driven pathogen prediction, and expansion into zoonotic disease surveillance. Partnerships with telehealth providers and development of cartridge‑free platforms also promise new revenue streams.

8. How is technology reshaping the market landscape?

Advances in CRISPR‑based detection, digital PCR, and microfluidic chip designs are reducing assay time and cost, while improving sensitivity. Cloud‑connected analytics enable real‑time epidemiological tracking, accelerating decision‑making for clinicians and public‑health agencies.

9. What regulatory trends influence the market’s future outlook?

Streamlined Emergency Use Authorization pathways and harmonized EU in‑vitro diagnostic regulations are expediting product launches. However, stricter clinical validation requirements and post‑market surveillance mandates are increasing compliance costs, shaping the market’s future outlook.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Molecular Diagnostics for Infectious Diseases Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	7.20 billion
Revenue forecast in 2033	18.21 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche Diagnostics; Illumina; Qiagen; Abbott Laboratories; BioMérieux; Cepheid (Danaher); Thermo Fisher Scientific; Hologic; DiaSorin; Luminex; Hoffmann-La Roche; Biocartis; Nanomix; BioFire Diagnostics; Seegene; QuidelOrtho; ZeptoMetrix; Sansure; BGI Genomics; DaAn Gene; Kehua Bio-engineering
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options